bioAffinity Technologies has received a Hong Kong patent for its CyPath Lung diagnostic platform, expanding intellectual property protection for its noninvasive lung cancer detection technology in the Asian market.
Initial results from a real-world study of the ProVue Lung test demonstrate 83% sensitivity for Stage I cancer in high-risk patients.
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Read More
University of Texas at Dallas researchers combine electrochemical biosensors with AI to identify volatile organic compounds linked to thoracic cancers.
Read More
The permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State, completing nationwide availability.
Read More
A new blood-based test that combines four protein markers with artificial intelligence has demonstrated potential for early lung cancer detection in a multicenter retrospective study.
Read More
On World Lung Day, Reveal Dx board member Mat Brevard discusses why current diagnostic tools fall short—and how new approaches could improve accuracy and outcomes.Â
Read More
The 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.
Read More
Haystack Oncology and Rutgers Cancer Institute collaborate on phase II trial examining minimal residual disease testing in stage II/III NSCLC patients.
Read More
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA’s potential to personalize consolidation immunotherapy decisions.
Read More
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read More
A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
Read More
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
Read More
The FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read More
Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read More
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Read More
Scientists have developed a low-cost, fast-response sensor capable of detecting lung cancer biomarkers from a blood sample in just 40 minutes.
Read More